A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of DP13 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs DP 13 (Primary)
- Indications Endocrine disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Damian Pharma
- 27 Jul 2017 Planned End Date changed from 1 Oct 2017 to 30 Jun 2018.
- 27 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
- 24 Feb 2017 Status changed from not yet recruiting to recruiting.